Vibostolimab (anti-TIGIT)

Synonyms: MK-7684

Catalog No.A2033 Purity:99%

Vibostolimab (anti-TIGIT, MK-7684) is a humanized monoclonal antibody that binds to the T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT), blocking the interaction between TIGIT and its ligands, CD112 and CD155, thereby activating T lymphocytes which help to destroy tumor cells.

Click to purchase the isotype control of Vibostolimab (anti-TIGIT)

Purity & Quality Control

Batch: Purity: 99% Protein concentration: 4.91mg/ml Endotoxin Level: ＜1EU/mg

Choose Selective Immunology & Inflammation related Inhibitors

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Vibostolimab (anti-TIGIT, MK-7684) is a humanized monoclonal antibody that binds to the T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT), blocking the interaction between TIGIT and its ligands, CD112 and CD155, thereby activating T lymphocytes which help to destroy tumor cells.

References
[1] J Niu, et al. Ann Oncol . 2021 Nov 17;S0923-7534(21)04776-1.

References

[1] J Niu, et al. Ann Oncol . 2021 Nov 17;S0923-7534(21)04776-1.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	2231305-30-7
Molecular Weight	145 kD
Isotype	Human IgG1, κ
Source	CHO cells
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20 mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.